PLoS ONE (Jan 2014)

An active learning approach for rapid characterization of endothelial cells in human tumors.

  • Raghav K Padmanabhan,
  • Vinay H Somasundar,
  • Sandra D Griffith,
  • Jianliang Zhu,
  • Drew Samoyedny,
  • Kay See Tan,
  • Jiahao Hu,
  • Xuejun Liao,
  • Lawrence Carin,
  • Sam S Yoon,
  • Keith T Flaherty,
  • Robert S Dipaola,
  • Daniel F Heitjan,
  • Priti Lal,
  • Michael D Feldman,
  • Badrinath Roysam,
  • William M F Lee

DOI
https://doi.org/10.1371/journal.pone.0090495
Journal volume & issue
Vol. 9, no. 3
p. e90495

Abstract

Read online

Currently, no available pathological or molecular measures of tumor angiogenesis predict response to antiangiogenic therapies used in clinical practice. Recognizing that tumor endothelial cells (EC) and EC activation and survival signaling are the direct targets of these therapies, we sought to develop an automated platform for quantifying activity of critical signaling pathways and other biological events in EC of patient tumors by histopathology. Computer image analysis of EC in highly heterogeneous human tumors by a statistical classifier trained using examples selected by human experts performed poorly due to subjectivity and selection bias. We hypothesized that the analysis can be optimized by a more active process to aid experts in identifying informative training examples. To test this hypothesis, we incorporated a novel active learning (AL) algorithm into FARSIGHT image analysis software that aids the expert by seeking out informative examples for the operator to label. The resulting FARSIGHT-AL system identified EC with specificity and sensitivity consistently greater than 0.9 and outperformed traditional supervised classification algorithms. The system modeled individual operator preferences and generated reproducible results. Using the results of EC classification, we also quantified proliferation (Ki67) and activity in important signal transduction pathways (MAP kinase, STAT3) in immunostained human clear cell renal cell carcinoma and other tumors. FARSIGHT-AL enables characterization of EC in conventionally preserved human tumors in a more automated process suitable for testing and validating in clinical trials. The results of our study support a unique opportunity for quantifying angiogenesis in a manner that can now be tested for its ability to identify novel predictive and response biomarkers.